Biotechnology Oversight Coordination Act of 2024

HR 8538 establishes a new interagency committee, chaired by the Office of Science and Technology Policy Director, to coordinate federal biotechnology regulation across agencies like USDA, FDA, and EPA. The committee must streamline oversight by creating clear regulatory pathways, reducing duplication, and developing a unified process to determine if biotech products could occur naturally. It requires annual reports to Congress detailing regulatory timelines, progress on coordination, and specific actions for emerging areas like molecular farming. The bill excludes human medical products regulated solely by the FDA and mandates a Comptroller General review to assess the committee's effectiveness. This aims to create a more predictable system for biotech developers while maintaining environmental and health protections.